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diagnosis and management of patients. In the field of chronic obstructive pulmonary disease (COPD) in particular, there is already a long history of clinical practice guidelines that have allowed physicians from any field to integrate knowledge and to apply the best evidence to their clinical practice. Many of these guidelines have regular updates, [1] [2] [3] and a few also have evaluation mechanisms for their implementation. 1 However, the volume of knowledge and complexity continues to increase, and a multidisciplinary approach to COPD that includes all stakeholders -including patients themselves -is necessary to try to reduce the huge burden of disease that leads to individual and collective morbidity and mortality.
On 6 October 2009 an integrated COPD Strategy of the National Health Service was adopted in Spain. 4 All scientific societies, patient organisations, and central and regional governments formed a partnership to enhance care and research in COPD. Related to this, since 2 January 2011 there is a new smoking law in Spain which is more consistent with European Union legislation, 5 and new plans of action against COPD in various regions started after this date. At the same time, the Spanish Society of Pneumology and Thoracic Surgery (SEPAR) took the initiative to convene the various scientific societies involved in the National COPD Strategy and invited them to participate in the development of the new Spanish guidelines for COPD (Guía Española de la EPOC (GesEPOC); www.gesepoc.com). 6 GesEPOC 7 is an ambitious project which is already generating a lively debate about new approaches to the treatment of COPD. We believe that our initiative might be of interest to other colleagues at the international level. This paper summarises the main new approaches of GesEPOC.
Organisation
GesEPOC has three basic areas of action: (1) Scientific-Medical, responsible for drafting recommendations aimed at diagnosis and treatment adapted to all levels of healthcare. The final document is structured based on scientific evidence and explicit recommendations that should facilitate their implementation according to the highest standards of care. The document also includes several indicators of quality of care for evaluation of the implementation. 6 (2) Patients, who are central in any training and self-care strategies, were also involved and developed information materials for patients through focal groups. (3) Communication, responsible for developing promotional materials, press releases and engaging social and economic factors to generate information about COPD and those who suffer. 7 As discussed above, representatives from all the scientific societies represented within GesEPOC (see Appendix 1, available online at www.thepcrj.org) discussed COPD treatment recommendations, which were updated on the basis of the advances that have emerged in recent years. Perhaps our more innovative approach is to base the treatment of stable COPD on clinical phenotypes, a term which has become increasingly used in recent years to refer to the different clinical forms of patients with COPD. Recently, a group of international experts defined clinical phenotypes of COPD as "… those attributes of the disease alone or in combination that describe the differences between individuals with COPD in relation to parameters that have clinical significance (symptoms, exacerbations, response to treatment, rate of progression disease, or death)". 8 The phenotype should therefore be able to classify patients into subgroups with prognostic value and determine the most appropriate therapy to achieve better results from a clinical standpoint.
Phenotypes of COPD
Many previous studies have attempted to identify and quantify the prevalence of different phenotypes of COPD using populations of various sources, severities, and particularities. 9 Yet there is no consensus on the number and definition of different phenotypes, from two to 210 million (the estimated number of patients worldwide). However, there must be a compromise between the oversimplification of the term COPD as a definition that encompasses the entire spectrum of patients with incompletely reversible airflow obstruction caused largely by smoking and the complexity of considering each patient individually as an orphan disease. 10 This intermediate step might arise by the identification and description of some phenotypes, not only in the biological or epidemiological sense but also from the prognostic and therapeutic point of view, especially at the individual patient level. After a lengthy but fruitful panel discussion, it was proposed that four different phenotypes of prognostic and therapeutic relevance characterised by the combination of the classical types of emphysema, chronic bronchitis, exacerbators and patients with overlap COPD-asthma be defined. 11 The proposed phenotypes are: (A) infrequent exacerbators with either chronic bronchitis or emphysema; (B) overlap COPD-asthma; (C) frequent exacerbators with emphysema predominant; and (D) frequent exacerbators with chronic bronchitis predominant ( Figure 1 ). We describe the rationale behind each of these four phenotypes, and their proposed treatment.
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Infrequent exacerbators with either chronic bronchitis or emphysema
Infrequent exacerbators are defined as patients experiencing <2 exacerbations per year. 13 The importance of identifying this phenotype is that there is currently no anti-inflammatory treatment indicated for infrequent exacerbators. The treatment of this phenotype is based on bronchodilators, alone or in combination, and together with theophyllines in severe cases.
Overlap COPD-asthma
The overlap COPD-asthma phenotype is characterised by incompletely reversible obstruction of airflow accompanied by symptoms or signals of increased reversibility of the obstruction. [14] [15] [16] Epidemiological studies of COPD incidence show that young patients with asthma who smoke and develop airflow obstruction that is not fully reversible (i.e. COPD) have a disease with different characteristics from those with no history of asthma. In the first case, allergic rhinitis, bronchial hyperresponsiveness, and the presence of wheezing as well as higher plasma concentrations of IgE are PRIMARY CARE RESPIRATORY JOURNAL www.thepcrj.org 119 significantly more frequent, indicating that this is an overlap phenotype between asthma and COPD. 17 Also, asthma by itself is a risk factor for the development of chronic airflow obstruction, particularly if undertreated, and in advanced stages may be indistinguishable from smokers' COPD. 18 The prevalence of this mixed phenotype is unknown, but there are different estimates of its importance in the context of COPD. COPDGene estimated it was 13% of their sample. 19 Soriano et al. estimated that approximately 23% of COPD patients aged 50-59 years could have a mixed phenotype, increasing to 52% of those with COPD aged 70-79 years. 9 The relevance of this phenotype, already described in the Canadian and Japanese guidelines, 2,3 is its enhanced response to inhaled corticosteroids, which must be prescribed together with long-acting bronchodilators irrespective of the severity of the airflow obstruction. Recently, a group of experts have proposed a series of criteria for the diagnosis of the overlap phenotype of asthma and COPD. 20 
Frequent exacerbators with emphysema or chronic bronchitis predominant
The COPD exacerbator phenotype refers to patients experiencing >2 exacerbations annually. 13 This phenotype is based on clinical records and/or patient recall, and it has been shown that diagnosis based on the patient's statement about his/her history of exacerbations is reliable. 21 The COPD exacerbator phenotype underscores the importance of asking about the history of exacerbations in the clinical interview and identifies patients who may require antiinflammatory treatment added to bronchodilators.
When the exacerbator patient does not present with chronic cough and sputum production and the typical clinical and radiological signs of emphysema can be identified (air trapping, dyspnoea, and a tendency to low body mass index), it constitutes the exacerbator with emphysema phenotype. The basis of pharmacological treatment is long-acting bronchodilators and, in some cases, with inhaled corticosteroids. The diagnosis of predominant emphysema can be established in patients without daily cough and sputum production and with clinical and radiographical signs of air trapping. In controversial cases, the determination of static lung volumes and/or a chest CT scan will be of help.
More frequently, the exacerbator will present with chronic bronchitis, 22 defined as the presence of productive cough or expectoration for >3 months a year and for more than two consecutive years. Bronchial hypersecretion in COPD has been associated with increased airway inflammation and increased risk of bronchial colonisation and respiratory infection, which may explain why patients with chronic bronchitis have an increased frequency of exacerbations. 23 These patients may be treated with bronchodilators, inhaled corticosteroids and, in contrast to exacerbators with emphysema, they respond to treatment with roflumilast. Selected cases with frequent exacerbations may respond to long-term treatment with macrolides 24 and, when inhaled corticosteroids cannot be used, mucolytics may be effective in reducing exacerbations.
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Assessment of severity
These phenotypes identify patients with different responses to the available treatments and allow a more personalised approach to treatment, which will be modulated by the severity. The assessment of severity has also been updated with the incorporation of multidimensional indices. The severity of obstruction, as measured by forced expiratory volume in 1 second (FEV 1) is essential but not sufficient. Multidimensional indices such as the BODE index (body mass index, airflow obstruction, dyspnoea, and exercise capacity) have demonstrated excellent prognostic value. 26, 27 If the 6-minute walking test is not performed routinely, its substitution by the frequency of exacerbations (BODEx index) provides similar prognostic properties. 28 For those physicians not familiar with indices, GesEPOC proposes to establish the severity of COPD based on the combination of FEV 1, dyspnoea measured by the modified MRC scale, level of physical activity quantified as the mean time in minutes that the patient walks per day, 29 and history of previous hospitalisations. 12 For all degrees of severity, the COPD Assessment Test (CAT) score and the number of exacerbations will serve as a marker of disease control. 30 A summary of the evaluation of severity is presented in Figure 2 . In GesEPOC we recommend directing the type of treatment by phenotype and the intensity of treatment by its severity, as shown in Table 1 .
A step to the future
We recognise that this approach represents a significant change in the management of COPD, from an approach focused on the severity of airflow limitation to a more personalised approach focused on clinical features and a multidimensional evaluation of severity. 31 Parallel to this clinical approach, GesEPOC wants to highlight the crucial role of patients and their caregivers in improving outcomes of care. To achieve the best possible results, it includes specific strategies such as a guide to COPD for patients, personalised action plans, and the performance of 'expert patients' PRIMARY CARE RESPIRATORY JOURNAL www.thepcrj.org or group visits directed to improve the skills and abilities in health of patients and caregivers. All of these strategies have been developed with the active participation of the Spanish associations of COPD patients. A change of this magnitude requires input and, finally, the consensus views of a significant number of professionals working with COPD and patients themselves. Since the beginning of the guideline process it has been presented at meetings and has received and integrated comments from more than 150 health professionals and independent reviewers.
GesEPOC was born with a desire for continuity, to explore new platforms for communication with physicians, patients, media and health authorities and the implementation and evaluation of their impact on the treatment of COPD, without forgetting its role in ICS=inhaled corticosteroids; LAMA=long-acting anticholinergic; LABA=long-acting β2-agonist; PDE4I=phosphodiesterase 4 inhibitor; SABA=short-acting β2-agonist; SAMA=short-acting anticholinergic. *In case of intermittent symptoms. spreading the awareness of this disease among the general population and at the political level. Together with the official website, the main aspects of the guideline will be available in the form of Apps for iPad, iPod, and Android. We hope that this initiative will contribute to the debate about new approaches to the management of COPD and will provide a more personalised treatment for patients with this frequent chronic disease.
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